Bladder Cancer, published by IOS PRESS, is a premier open access journal dedicated to advancing the field of oncology and urology, with a specific focus on bladder cancer research and treatment. Established in 2015 and continuing through to 2024, this journal aims to disseminate high-quality, peer-reviewed research that contributes to the understanding, diagnosis, and management of bladder cancer, a critical area of concern in urological oncology. With a robust publication record now encompassing open access since 2023, Bladder Cancer ensures accessibility to vital research for clinicians, researchers, and scholars worldwide. The journal's rankings in Scopus reflect its commitment to excellence, holding a Q3 category in both oncology and urology, with Scopus ranks of #78 in Urology and #285 in Oncology, showcasing its growing influence in the scientific community. By fostering dialogue and innovation, Bladder Cancer serves as an essential resource for those committed to improving patient outcomes in bladder oncology.

Research and Reports in Urology, published by DOVE MEDICAL PRESS LTD, is a premier journal dedicated to the dissemination of cutting-edge research and clinical advancements in the field of urology. With an impressive impact factor and a recognized status as Q2 within the urology category, this journal offers a vital platform for researchers, practitioners, and students eager to engage with the latest findings and methodologies. Since its inception in 2009, the journal has embraced an Open Access model, ensuring that critical research is freely available to the global community, thereby fostering collaboration and innovation in urological science. Based in New Zealand, it operates within a robust international framework, allowing for a diverse range of contributions that address pressing issues in urology and enhance professional knowledge. Researchers are encouraged to submit their work and become part of this influential discourse, as the journal continues to navigate the rapidly evolving landscape of urological health from 2012 to 2024 and beyond.

Translational Andrology and Urology is a premier journal published by AME Publishing Company, dedicated to advancing research in the fields of reproductive medicine and urology. Established in 2012 and gaining prominence with its Q2 rankings in both the reproductive medicine and urology categories as of 2023, this journal serves as a vital platform for disseminating groundbreaking studies and clinical advancements. With an ISSN of 2223-4683 and an E-ISSN of 2223-4691, it is indexed in Scopus, standing at a distinguished rank of #40/120 in Urology and #33/90 in Reproductive Medicine. Located in Hong Kong, the journal reflects a commitment to open access and international collaboration, providing researchers, professionals, and students with critical insights and updates in these dynamic fields. As a leading resource, Translational Andrology and Urology invites contributions that explore innovative approaches that can enhance patient care and clinical practices.

Urology Annals, published by Wolters Kluwer Medknow Publications, is a premier open-access journal dedicated to advancing the field of urology through high-quality research and clinical insights. Established in India in 2009, this journal serves as a vital platform for communication among urologists, researchers, and medical professionals, aiming to enhance understanding and innovation in urological sciences. With an ISSN of 0974-7796 and an E-ISSN of 0974-7834, the journal offers unrestricted access to its content, fostering knowledge dissemination and collaboration across the global medical community. Currently ranked in the Q3 category within urology and holding a Scopus rank of #79/120, Urology Annals showcases significant contributions that align with its mission to publish original research, reviews, and case reports that address contemporary challenges in urology. The journal's ongoing commitment to remaining a leading resource in the field is reflected through its convergence of years from 2010 to 2024, ensuring that it stays at the forefront of the latest urological advancements.

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

American Journal of Clinical and Experimental Urology is a pivotal platform for the dissemination of cutting-edge research in the field of urology. Published by E-CENTURY PUBLISHING CORP, this peer-reviewed journal aims to enhance the understanding and application of clinical and experimental practices in urological science. The journal prioritizes high-quality, original research articles, reviews, and case studies that provide valuable insights for urologists, researchers, and healthcare professionals alike. With an increasing focus on evidence-based approaches to urological health, AJCEU serves as an essential resource for those who strive to advance diagnostic and therapeutic methodologies. Though currently not indexed in major databases, the journal is committed to expanding its reach within the academic community, thus fostering collaboration and innovation in urology. The open access model allows for broader distribution and engagement with the latest findings in the field, making it an indispensable tool for scholars and practitioners dedicated to advancing urological care and research.

EUROPEAN UROLOGY is a prestigious journal in the field of urology, published by Elsevier, and residing in the vibrant academic landscape of the Netherlands. Since its inception in 1975, the journal has made significant contributions to urological research, earning a top rank of #1 out of 120 in the Scopus category of Medicine - Urology, placing it within the esteemed 99th percentile of its field. With a commitment to disseminating cutting-edge research, clinical findings, and innovative practices, EUROPEAN UROLOGY has established itself as a pivotal resource for urologists and researchers alike. Although it does not offer open access options, it provides an indispensable platform for scholarly communication that drives advancements in patient care and medical knowledge. As the journal embarks on converged years leading up to 2024, it continues to strive for excellence in urology, welcoming contributions that reflect the latest scientific advancements and clinical applications.

UROLOGY is a prestigious journal published by Elsevier Science Inc, renowned for disseminating high-quality research and reviews in the field of urology. With an ISSN of 0090-4295 and E-ISSN 1527-9995, this journal has been a trusted resource since its inception in 1973 and continues to provide insights into the latest advancements and clinical practices in urology, maintaining a category quartile of Q2 as of 2023. The journal ranks 50th out of 120 in the Scopus metrics for Medicine - Urology, placing it in the 58th percentile, which underscores its influence and relevance in the academic community. Although it is not structured as an open access journal, it offers a wealth of knowledge vital for researchers, healthcare professionals, and students alike, enabling them to stay abreast of evolving treatments and innovations in the field. As we move towards 2024, UROLOGY remains committed to advancing research and enhancing practices in urological care, fostering a collaborative environment among its readership.

BMC Urology is a premier open-access journal dedicated to advancing research in the field of urology, reproductive medicine, and miscellaneous aspects of medicine. Published by BMC since 2001 and based in the United Kingdom, this journal provides a platform for researchers, clinicians, and students to disseminate their findings and explore the latest innovations and advancements within these vital fields. With a notable impact factor and categorization in the Q2 quartile for various categories of medicine, BMC Urology stands as a reputable source, ranking 51st out of 120 in Urology and 44th out of 90 in Reproductive Medicine according to Scopus metrics. The journal fosters knowledge sharing through its open-access model, ensuring that research is accessible to all. As it converges from 2001 to 2024, BMC Urology continues to play a crucial role in shaping the landscape of urological research and providing invaluable insights into clinical practices.

Canadian Journal of Urology, published by CANADIAN J UROLOGY, is a prominent peer-reviewed journal dedicated to advancing the field of urology and its allied disciplines. Established in 2000, this journal has consistently aimed to provide a platform for comprehensive research, clinical studies, and innovative practices in urology and general medicine, ensuring that professionals remain at the forefront of medical advancements. With a reputation reflected in its 2023 Scopus ranking of Q3 in both Urology and Medicine (miscellaneous), the journal serves as an essential resource for researchers and practitioners seeking to enhance their knowledge and application of urological sciences. Although it is not an Open Access journal, its impactful findings contribute significantly to the medical community in Canada and beyond, promoting evidence-based practices and contributing to better patient outcomes. As the journal converges into 2024, it continues to welcome high-quality submissions that explore critical challenges and advancements in urology.